Centessa Pharmaceuticals plc CNTA
40.50 USD 0.00 (+0.00%)
At closeJun 25, 2026, 4:00 PM EDT
40.68 +0.18 +0.45%
After hours · Jun 25, 4:00 PM ET
40.50 Day range 40.50
52-week range unavailable
- YTD
- +61.94%
- 1 year
- +201.56%
Analyst view
Price target (mean) —
Ratings (0m) 7 2 buy · 5 hold · 0 sell
- Strong buy1
- Buy1
- Hold5
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 13
- 2 months ago 13
- 3 months ago 13
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.39 | -0.39 – -0.39 | -0.38 | -2.6% | 0 | 0.0% | 1 |
| Next quarter | -0.39 | -0.39 – -0.39 | -0.41 | +4.9% | 0 | 0.0% | 1 |
| Current year | -1.56 | -1.56 – -1.56 | -1.46 | -6.9% | 0 | -100.0% | 1 |
| Next year | -1.78 | -2.06 – -1.30 | -1.56 | -14.1% | 28.57M | 0.0% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 20, 2026 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Apr 2, 2026 | Guggenheim | Downgrade | Buy | Neutral |
| Apr 1, 2026 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Mar 31, 2026 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Mar 31, 2026 | Needham | Downgrade | Buy | Hold |
| Feb 24, 2026 | Wolfe Research | Initiated | — | Outperform |
| Jan 29, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jan 8, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jan 2, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Jan 2, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Dec 10, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Dec 1, 2025 | B. Riley Securities | Maintained | Buy | Buy |
| Nov 18, 2025 | Guggenheim | Maintained | Buy | Buy |
| Nov 13, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Nov 7, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Oct 28, 2025 | Stephens & Co. | Initiated | — | Overweight |
| Oct 6, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Sep 3, 2025 | Wells Fargo | Initiated | — | Overweight |
| Aug 12, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Jul 30, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Jul 21, 2025 | Truist Securities | Initiated | — | Buy |
| May 28, 2025 | Needham | Initiated | — | Buy |
| May 8, 2025 | Chardan Capital | Initiated | — | Buy |
| Mar 31, 2025 | Piper Sandler | Initiated | — | Overweight |
| Mar 26, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Feb 10, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Jan 7, 2025 | TD Cowen | Initiated | — | Buy |
| Nov 15, 2024 | Guggenheim | Maintained | Buy | Buy |
| Sep 19, 2024 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| Sep 19, 2024 | B. Riley Securities | Initiated | — | Buy |